NO961536L - Preparation of bisphosphonates and growth hormone secretagogue - Google Patents

Preparation of bisphosphonates and growth hormone secretagogue

Info

Publication number
NO961536L
NO961536L NO961536A NO961536A NO961536L NO 961536 L NO961536 L NO 961536L NO 961536 A NO961536 A NO 961536A NO 961536 A NO961536 A NO 961536A NO 961536 L NO961536 L NO 961536L
Authority
NO
Norway
Prior art keywords
bisphosphonates
growth hormone
preparation
hormone secretagogue
secretagogue
Prior art date
Application number
NO961536A
Other languages
Norwegian (no)
Other versions
NO961536D0 (en
Inventor
Barry J Gertz
Gideon A Rodan
Roy G Smith
Matthew J Wyvratt
Arthur A Patchett
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO961536D0 publication Critical patent/NO961536D0/en
Publication of NO961536L publication Critical patent/NO961536L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bisfosfonater i kombinasjon med veksthormonsekretagoga reduserer de skadelige effektene av osteoporose hos eldre pasienter.Bisphosphonates in combination with growth hormone secretagogue reduce the deleterious effects of osteoporosis in elderly patients.

NO961536A 1993-10-19 1996-04-18 Preparation of bisphosphonates and growth hormone secretagogue NO961536L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13929693A 1993-10-19 1993-10-19
US25909194A 1994-06-13 1994-06-13
PCT/US1994/011912 WO1995011029A1 (en) 1993-10-19 1994-10-18 Combination of bisphosphonates and growth hormone secretagogues

Publications (2)

Publication Number Publication Date
NO961536D0 NO961536D0 (en) 1996-04-18
NO961536L true NO961536L (en) 1996-06-18

Family

ID=26837073

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961536A NO961536L (en) 1993-10-19 1996-04-18 Preparation of bisphosphonates and growth hormone secretagogue

Country Status (16)

Country Link
EP (1) EP0813414A4 (en)
JP (1) JPH09504525A (en)
KR (1) KR960705575A (en)
CN (1) CN1136278A (en)
AU (1) AU8083694A (en)
BG (1) BG100517A (en)
BR (1) BR9407869A (en)
CA (1) CA2173333A1 (en)
CZ (1) CZ109196A3 (en)
FI (1) FI961681A (en)
HU (1) HUT75224A (en)
LV (1) LV11432B (en)
NO (1) NO961536L (en)
PL (1) PL314003A1 (en)
SK (1) SK49796A3 (en)
WO (1) WO1995011029A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
JP3133073B2 (en) * 1995-05-29 2001-02-05 ファイザー・インコーポレーテッド Dipeptides that stimulate growth hormone release
AU7522896A (en) * 1995-10-27 1997-05-15 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
CA2240186A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS
IL126983A0 (en) * 1996-05-31 1999-09-22 Novo Nordisk As Growth hormone components and bone anti-resorptive agent in cyclic (coherence) treatment of osteoporosis
AU4993497A (en) * 1996-10-25 1998-05-22 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
IT1296495B1 (en) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa USE OF BISPHOSPHONATES IN THE PREPARATION OF PHARMACEUTICAL FORMS FOR INTRAMUSCULAR ADMINISTRATION
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
JP2002520011A (en) 1998-07-13 2002-07-09 メルク・アンド・カンパニー・インコーポレーテッド Growth hormone secretagogue-related receptors and nucleic acids
WO2000009538A2 (en) 1998-08-10 2000-02-24 Merck & Co., Inc. Canine growth hormone secretagogue receptor
AU2686899A (en) * 1998-08-18 2000-03-14 Eli Lilly And Company Growth hormone secretagogues
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
AR013994A1 (en) * 1998-10-30 2001-01-31 Gador Sa PROCEDURE AND PREPARATIONS THAT SELECTIVELY MODULATE THE FUNCTION OF THE OSTEOBLASTO FOR THE PREVENTION AND TREATMENT OF FRAGILIZING OSTEOPATHIES.
US6416737B1 (en) * 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
AU4782600A (en) * 1999-06-02 2000-12-28 Procter & Gamble Company, The Oral preparations of etidronate disodium
DE60140285D1 (en) 2000-05-31 2009-12-10 Pfizer Prod Inc Use of growth hormone secretagogues to promote the mobility of the digestive tract
US6548042B2 (en) 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
MXPA03006565A (en) 2001-01-23 2005-07-29 Gador Sa Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof.
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
DE60306636T2 (en) 2002-04-09 2007-07-05 Eli Lilly And Co., Indianapolis WACHSTUMHORMONSEKRETIONSFÖRDERER
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
CA2524610C (en) * 2003-05-07 2014-03-25 Osteologix A/S Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
WO2006023852A2 (en) 2004-08-19 2006-03-02 Vertex Pharmaceuticals, Incorporated Modulators of muscarinic receptors
KR20070086756A (en) 2004-11-29 2007-08-27 버텍스 파마슈티칼스 인코포레이티드 Modulators of muscarinic receptors
CA2634456A1 (en) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
NZ570497A (en) 2006-02-22 2011-09-30 Vertex Pharma Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
CN101426499A (en) 2006-02-22 2009-05-06 弗特克斯药品有限公司 Modulators of muscarinic receptors
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
US7858790B2 (en) 2006-06-29 2010-12-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7696201B2 (en) 2006-08-15 2010-04-13 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP2051715A2 (en) 2006-08-18 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
ES2602789T3 (en) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Connector intermediates for the synthesis of macrocyclic modulators of the ghrelin receptor
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
JP2010540640A (en) 2007-10-03 2010-12-24 バーテックス ファーマシューティカルズ インコーポレイテッド Muscarinic receptor modulators
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
MX2020013236A (en) 2018-06-06 2021-02-22 Massachusetts Inst Technology Circular rna for translation in eukaryotic cells.
BR112021023411A2 (en) 2019-05-22 2022-02-01 Massachusetts Inst Technology Compositions and methods of circular rna
AU2020397956A1 (en) 2019-12-04 2022-07-07 Orna Therapeutics, Inc. Circular RNA compositions and methods
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU568433B2 (en) * 1984-04-30 1987-12-24 Procter & Gamble Company, The Treating osteoporosis
AU569391B2 (en) * 1984-04-30 1988-01-28 Procter & Gamble Company, The Treating osteoporosis
WO1994013696A1 (en) * 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) * 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5545735A (en) * 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone

Also Published As

Publication number Publication date
HU9601013D0 (en) 1996-06-28
EP0813414A4 (en) 1999-07-21
SK49796A3 (en) 1997-05-07
FI961681A0 (en) 1996-04-17
AU8083694A (en) 1995-05-08
NO961536D0 (en) 1996-04-18
KR960705575A (en) 1996-11-08
BR9407869A (en) 1996-10-29
HUT75224A (en) 1997-04-28
FI961681A (en) 1996-06-12
LV11432A (en) 1996-08-20
CN1136278A (en) 1996-11-20
BG100517A (en) 1996-11-29
CZ109196A3 (en) 1996-10-16
PL314003A1 (en) 1996-08-05
WO1995011029A1 (en) 1995-04-27
CA2173333A1 (en) 1995-04-27
JPH09504525A (en) 1997-05-06
LV11432B (en) 1996-12-20
EP0813414A1 (en) 1997-12-29

Similar Documents

Publication Publication Date Title
NO961536L (en) Preparation of bisphosphonates and growth hormone secretagogue
AU3022692A (en) Methods for the treatment of osteoporosis using bone-active phosphonates and parathyroid hormone
AU8904491A (en) Foot and leg splint device
DE69527672D1 (en) Brace for correcting the foot and footwear with this brace
AU2905592A (en) Foot orthosis and method
IT8819961A0 (en) MODULAR COMPOSITE PROSTHETIC DEVICE FOR LEG AND FOOT.
AU6094096A (en) Use of gamma-hydroxybutyrate for the stimulation of sleep-re lated growth hormone secretion
DE69217736D1 (en) Inhibited acryloxy and methacryloxysilanes
IL138665A0 (en) Peptide factor
DE69418504T2 (en) Double fixation prosthesis
DK487587A (en) FLUORED AND CALCIUM AGENTS WITH DELAYED DELIVERY
IL101587A0 (en) Biologically active peptide composition and uses therefor
ZA936692B (en) Physiologically active peptide composition
AU9052991A (en) Use of angiotensin ii antagonist in the treatment of infarction
MX9805506A (en) Novel medical use of an ace-inhibitor for treatment of dyspeptic symptoms.
AU9084191A (en) Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke
ZA941199B (en) Physiologically active compound HS-1 and process for the preparation of the same
NO167146C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE CONDENSED DIAZEPINONES.
AU9034291A (en) Derivates of the human parathormone fragment (1-37) in the amide or ethylamide form as active substance
NO165493C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE CHINAZOL INDIA AND PYRIDOPYRIMID INDIA.
NO921086L (en) PROCEDURE FOR THE PREPARATION AND USE OF SUBSTITUTED 2 ', 3'-DIDESOXY-5-TRIFLUORMYTYLURIDINES
NO903939L (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE CONDENSED DIAZEPINONES.
ES2094930T3 (en) NEW TROMBINE INHIBITING PROTEIN ISOLATED FROM TICKS.
IL86156A0 (en) Preparation of l-phenylalanine with the aid of recombinant bacteria
AU9056191A (en) Foot warmer insole and method